ASCO Annual Meeting 2024: New Potential Standard of Care for Lymphomas

Introduction

New research presented at the ASCO Annual Meeting 2024 has revealed a potential new standard of care for Hodgkin lymphoma, as well as treatment options for diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and natural killer/T-cell lymphoma (NKTCL). In this article, we will provide a detailed overview of the research presented and its potential impact on healthcare.

Brentuximab Vedotin Plus Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone (BrECADD)

Research conducted in a phase 3 GHSG HD

Originally Post From https://www.cancertherapyadvisor.com/indepth/asco-2024-lymphoma-advances/

Read more about this topic at
Treatment Options for Lymphoma
Lymphoma: Symptoms, Causes and Treatment